IDTA (IDTA) Stock Price & Analysis
IDTA (IDTA) rose 0.00% to USD 0.36 as of September 9, 2026 at 03:13 UTC, according to Nexqual real-time market data.
IDTA last closed at USD 0.36; the session ranged USD 0.27–0.35 on volume of 7,502 shares. Market capitalization is $1.56M, with a 52-week range of USD 0.15–0.36 (OQB). Source: Nexqual, September 9, 2026 at 03:13 UTC.
Key Statistics (as of September 9, 2026 at 03:13 UTC)
| Price | USD 0.36 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0.36 |
| Open | USD 0.27 |
| Day Range | USD 0.27 – 0.35 |
| 52-Week Range | USD 0.15 – 0.36 |
| Volume | 7,502 shares |
| Market Cap | $1.56M |
| Exchange | OQB |
Technical Analysis (IDTA)
Nexqual's technical model rates IDTA "BUY" based on 5 bullish and 2 bearish signals across 127 daily candles, as of September 9, 2026 at 03:13 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 100 (overbought) |
| vs SMA50 | Above (USD 0.27) |
| MACD | 0.03 (positive) |
Analyst Ratings (IDTA)
Wall Street analysts rate IDTA "None", per Nexqual as of September 9, 2026 at 03:13 UTC.
| Consensus Rating | None |
|---|
Earnings (IDTA)
Source: Nexqual, September 9, 2026 at 03:13 UTC.
Financials & Fundamentals (IDTA)
| Total Revenue | $1.86M |
|---|---|
| Revenue Growth (YoY) | +50.50% |
| Gross Margin | +51.89% |
| Operating Margin | +4.68% |
| Profit Margin | +7.58% |
| ROE | +13.78% |
| Debt / Equity | 49.89 |
| Current Ratio | 4.32 |
| Total Cash | $1.10M |
| Total Debt | $648,994 |
| Free Cash Flow | $163,073 |
Source: Nexqual, September 9, 2026 at 03:13 UTC.
Financial Health Score (IDTA)
Nexqual rates IDTA's overall financial health "Solid" across five dimensions, as of September 9, 2026 at 03:13 UTC.
| Growth | Strong — Revenue +51% YoY (latest Q) |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $1M cash, no debt |
| Cash Flow | Solid — FCF $163K, 9% margin |
| Efficiency | Mixed — ROE 14%, ROA 10.6% |
Ownership (IDTA)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 4.37M |
Source: Nexqual, September 9, 2026 at 03:13 UTC.
Leadership (IDTA)
IDTA is led by Amichai Glattstein, CEO & Director, per Nexqual as of September 9, 2026 at 03:13 UTC.
| CEO & Director | Amichai Glattstein |
|---|---|
| Co-Founder, CTO & Chief Science Officer | Baruch Glattstein |
| Chief Operating Officer | Mishael Spitzer |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| HTDS | HARD TO TREAT DISEASES INC | USD 0 | ▲ 0% |
| ASFX | AMERICAN SCIENTIFIC RESOURCES I | USD 0 | ▲ 0% |
| IGNT | INGEN TECHNOLOGIES INC | USD 0 | ▲ 0% |
| OWVI | One World Ventures, Inc. | USD 0 | ▲ 0% |
| LLBO | Lifeline BioTechnologies, Inc. | USD 0 | ▲ 60% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 9, 2026 at 03:13 UTC. This page is informational and not investment advice.